AbbVie scores EU recommendation for shorter treatment of Viekirax in hepatitis C
pharmafile | July 25, 2016 | News story | Research and Development, Sales and Marketing | EU, Gilead, Viekirax, hepatitis C
AbbVie has received an EU recommendation for a shorter treatment duration of Viekirax (ombitasvir/paritaprevir/ritonavir) plus ribavirin in genotype 4 chronic hepatitis C virus infected adult patients with compensated cirrhosis.
Chronic hepatitis C virus affects more than 160 million people worldwide, with 34 million living with the genotype 4 form of the virus. This genotype is becoming increasingly common across Mediterranean countries, especially, where prevalence rates from 10 to 24% have been reported.
Currently approved on a 24 week regimen, this new recommendation has taken a positive stance on a 12 week treatment duration for Viekirax plus ribavirin. This opinion is supported by data from the Phase III AGATE-I study where 97% of patients achieved sustained virologic response at 12 weeks post-treatment.
Michael Severino, chief scientific officer at AbbVie, says: “Through optimising the use of Viekirax, AbbVie strives to meet the needs of patients and physicians, including a shortened treatment duration. This milestone is progress toward an approval that would allow us to provide the opportunity for a cure with just 12 weeks of our regimen to genotype 4 patients with or without compensated cirrhosis in Europe.”
Tarik Asselah, lead study author, adds: “Until recently people living with genotype 4 chronic hepatitis C had limited treatment options. If approved, this 12-week treatment would mark another step forward in the cure for GT4 patients, allowing difficult-to-cure patients with compensated cirrhosis to be treated in half the time with Viekirax, representing a significant benefit for both them and their patients.”
Sean Murray
Related Content
Gilead’s HIV treatment meets primary trial endpoint
Gilead has announced positive topline results from its phase 3 ARTISTRY-2 trial, which evaluated a …
Gilead announces first shipments of HIV prevention drug to Eswatini and Zambia
Gilead has announced the first shipments of its HIV prevention drug lenacapavir to Eswatini and …
Sharp invests $100m in US and EU manufacturing and packaging facilities
Sharp Services, a pharmaceutical packaging and sterile manufacturing specialist, has announced investments totalling $100m across …
